While the addition of Genentech's Avastin (bevacizumab) to the chemotherapy agent paclitaxel slowed the progression of tumors in women with metastatic breast cancer, it did not prolong the patients' overall survival and increased their risk of adverse events and death, drug regulators said. (BioWorld Today)

While the addition of Genentech's Avastin (bevacizumab) to the chemotherapy agent paclitaxel slowed the progression of tumors in women with metastatic breast cancer, it did not prolong the patients' overall survival and increased their risk of adverse events and death, drug regulators said. (BioWorld Today)